Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein

Clinical and Experimental Immunology

Volumn 104, Issue 2, 1996, Pages 269-274

  Vaarala, O ^a   Puurunen, M ^a   Lukka, M ^a   Alfthan, G ^a   Leirisalo Repo, M ^b   Aho, K ^a   Palosuo, T ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Anticardiolipin antibodies; Antiphospholipid antibodies; Erythematosus; Oxidized low density lipoprotein; Systemic lupus; 2 glycoprotien I

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY;

ADULT; AFFINITY CHROMATOGRAPHY; ANTIBODY AFFINITY; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0029874687     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.21728.x     Document Type: Article

References (26)

1. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49:193-280.
2. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341:923-5.
3. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88:1785-92.
4. Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60:221-5.
5. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine 1989; 68:141-50.
6. Palinski W, Rosenfeld ME, Ylä-Herttuala S et al. Low-density lipoprotein undergoes oxidative modifications in vivo. Proc Natl Acad Sci USA 1989; 86:1372-6.
7. Ylä-Hertluala S, Palinski W, Rosenfeld ME et al. Evidence for the presence of oxidatively modified LDL in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 85:1086-95.
8. Palinski W, Ylä-Herttuala S, Rosenfeld ME et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990; 10:325-35.
9. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984; 83:3883-7.
10. 2 activity in endothelial cell induced modification of LDL. Proc Natl Acad Sci USA 1985; 82:3000-4.
11. Matsuura E, Katahira T, Igarashi Y, Koike T. β2-glycoprotein I bound to oxidatively modified lipoproteins could be targeted by anticardiolipin antibodies. Lupus 1994; 3:314.
12. Puurunen M, Mänttäri M, Manninen V et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154:2605-9.
13. Vaarala O, Mänttäri M, Manninen V et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91:23-27.
14. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87:4120-4.
15. Harris EN, Gharavi AE, Patel SPR, Hughes GRV. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68:215-22.
16. Vaarala O, Julkunen H, Tenkanen L et al. Antibodies to oxidised low-density lipoprotein are not associated with thrombosis in patients with SLE. Lupus 1994; 3:321.
17. Shousboe I. β2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66:1086-91.
18. Polz E. Isolation of a specific lipid-binding protein from human affinity chromatography using heparin-Sepharose. In: Peeters H, ed. Protides of biological fluids. Oxford: Pergamon Press, 1979: 817-20.
19. Hunt JE, Krilis SA. The fifth domain of β2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognised by anticardiolipin antibodies. J Immunol 1994; 152:653-9.
20. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344:793-5.
21. Fogelman AM, Schechter I, Saeger J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 1980; 77:2214-8.
22. Haberland ME, Olch CL, Fogelman AM. Role of lysines in mediating interaction of modified low density lipoprotein with the scavenger receptor of human monocyte macrophages. J Biol Chem 1984; 259:11305-11.
23. Parums DV, Brown DL, Mitchison MJ. Serum antibodies to oxidized low density lipoprotein and ceroid in human periaortitis. Arch Pathol Lab Med 1990; 114:383-7.
24. Salonen JT, Ylä-Herttuala S, Yamamoto R et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992; 339:883-7.
25. Maggi E, Chiesa R, Melissano G et al. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arteriosder Thromb 1994; 14:1892-9.
26. Kabakov AE, Tertov VV, Saenko VA, Poverenny AM, Orekhov AN. The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells for human aorta. Clin Immunol Immunopathol 1992; 63:214-20.